ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in …

2013年1月6日 · Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199. This compound inhibits the growth of …

ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest …

2016年1月28日 · Souers, AJ, Leverson, JD, Boghaert, ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-208

2014年12月11日 · Here, we evaluated B-cell lymphoma (BCL)-2 inhibition by the BH3 mimetic ABT-199 as a new therapeutic strategy in human T-ALL. The T-ALL cell line LOUCY, which …

Here, we demonstrate that acute myeloid leukemia (AML) cell lines, primary patient samples, and murine primary xenografts are very sensitive to treatment with the selective BCL-2 antagonist …

2014年12月6日 · ABT-199 is a selective, orally bioavailable BCL-2 inhibitor that rapidly induces responses in ~80% of patients (pts) with relapsed/refractory (R/R) CLL or small lymphocytic …

2014年5月20日 · ABT-199 is an orally bioavailable, selective Bcl-2 inhibitor that triggers apoptosis of CLL cells in vitro and in vivo, making it a promising agent for the treatment of patients (pts) …

JS ABT-199 is a small-molecule, highly specific inhibitor of intracellular interactions with the B-cell lymphoma 2 (Bcl-2) protein. Bcl-2 is a molecule involved in the physiologic process of …

2013年11月15日 · ABT-199 (GDC-0199), a second-generation BH3 mimetic, has higher affinities for BCL-2 protein (Ki < 0.01 nM), which enhances the specificity of this agent to kill cancer …